1. Report Introduction
2. Indolent Lymphoma Market Overview at Glance
3. Disease Background and Overview: Indolent Lymphoma
3.1. Introduction
3.2. Signs and Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnostic Landscape
3.6.1. Diagnostic Practices
3.6.2. Diagnostic Criteria
3.6.3. Diagnostic Recommendations
3.7. Treatment Landscape
3.7.1. Current Treatment Practices
3.7.2. Treatment Algorithm
3.7.3. Treatment Recommendations
4. Indolent Lymphoma Epidemiology
4.1. Key Findings
4.2. Assumptions & Rationale
4.3. 7MM Epidemiology
5. Epidemiology of Indolent Lymphoma by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of Indolent Lymphoma
5.1.3. Sub-Type Specific cases of Indolent Lymphoma*
5.1.4. Sex- Specific Cases of Indolent Lymphoma*
5.1.5. Diagnosed Cases of Indolent Lymphoma
5.1.6. Treatable Cases of Indolent Lymphoma
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Prevalent/Incident Cases of Indolent Lymphoma
5.2.3. Sub-Type Specific cases of Indolent Lymphoma*
5.2.4. Sex- Specific Cases of Indolent Lymphoma*
5.2.5. Diagnosed Cases of Indolent Lymphoma
5.2.6. Treatable Cases of Indolent Lymphoma
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Prevalent/Incident Cases of Indolent Lymphoma
5.3.3. Sub-Type Specific cases of Indolent Lymphoma*
5.3.4. Sex- Specific Cases of Indolent Lymphoma*
5.3.5. Diagnosed Cases of Indolent Lymphoma
5.3.6. Treatable Cases of Indolent Lymphoma
5.4. United Kingdom
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of Indolent Lymphoma
5.4.3. Sub-Type Specific cases of Indolent Lymphoma*
5.4.4. Sex- Specific Cases of Indolent Lymphoma*
5.4.5. Diagnosed Cases of Indolent Lymphoma
5.4.6. Treatable Cases of Indolent Lymphoma
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of Indolent Lymphoma
5.5.3. Sub-Type Specific cases of Indolent Lymphoma*
5.5.4. Sex- Specific Cases of Indolent Lymphoma*
5.5.5. Diagnosed Cases of Indolent Lymphoma
5.5.6. Treatable Cases of Indolent Lymphoma
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of Indolent Lymphoma
5.6.3. Sub-Type Specific cases of Indolent Lymphoma*
5.6.4. Sex- Specific Cases of Indolent Lymphoma*
5.6.5. Diagnosed Cases of Indolent Lymphoma
5.6.6. Treatable Cases of Indolent Lymphoma
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of Indolent Lymphoma
5.7.3. Sub-Type Specific cases of Indolent Lymphoma*
5.7.4. Sex- Specific Cases of Indolent Lymphoma*
5.7.5. Diagnosed Cases of Indolent Lymphoma
5.7.6. Treatable Cases of Indolent Lymphoma
6. Unmet Needs
7. Marketed Drugs
7.1. Drug 1
7.1.1. Product Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Safety and Efficacy
7.1.5 Side-Effects
7.1.6. Product Profile
7.1.7. Sales
7.1.8. Patent Data
8. Emerging Drugs
8.1. Drug 1
8.1.1. Product Description
8.1.2. Clinical Trial Information and Results
8.1.3. Product Development Activity
8.1.4. Regulatory Milestones
8.1.5. Product Profile
8.1.6. Expected Launch Date
9. Country Specific Market Analysis
9.1. 7 Major Market Analysis
9.1.1. 7 Major Market Size
9.1.2. Therapy Wise Market Size
9.2. United States Market Analysis
9.2.1. United States Market Size
9.2.2. Therapy Wise Market Size
9.3. Germany Market Analysis
9.3.1. Germany Market Size
9.3.2. Therapy Wise Market Size
9.4. France Market Analysis
9.4.1. France Market Size
9.4.2. Therapy Wise Market Size
9.5. United Kingdom Market Analysis
9.5.1. United Kingdom Market Size
9.5.2. Therapy Wise Market Size
9.6. Spain Market Analysis
9.6.1. Spain Market Size
9.6.2. Therapy Wise Market Size
9.7. Italy Market Analysis
9.7.1. Italy Market Size
9.7.2. Therapy Wise Market Size
9.8. Japan Market Analysis
9.8.1. Japan Market Size
9.8.2. Therapy Wise Market Size
10. Market Drivers
11. Market Barriers
12. Market Opportunities
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.